NCT05583071View on ClinicalTrials.gov

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

April 30, 2027

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

Tafasitamab

IV

DRUG

Lenalidomide

Oral

DRUG

Rituximab

IV

DRUG

Methotrexate

IV

Trial Locations (6)

12203

NOT_YET_RECRUITING

Charité - Universitätsmedizin Berlin, Berlin

20246

NOT_YET_RECRUITING

Universitätsklinikum Hamburg-Eppendorf, Hamburg

45147

NOT_YET_RECRUITING

Universitätsklinikum Essen, Essen

50937

NOT_YET_RECRUITING

University of Cologne, Cologne

70174

RECRUITING

Klinikum Stuttgart - Katharienenhospital, Stuttgart

79106

NOT_YET_RECRUITING

Universitätsklinikum Freiburg, Freiburg im Breisgau

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

University of Cologne

OTHER